ValuEngine lowered shares of Humana Inc. (NYSE:HUM) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.
Other analysts have also recently issued reports about the stock. UBS AG reiterated a neutral rating and issued a $237.00 target price (up from $205.00) on shares of Humana in a research note on Wednesday, June 28th. BidaskClub cut shares of Humana from a buy rating to a hold rating in a research note on Tuesday, June 13th. Zacks Investment Research cut shares of Humana from a hold rating to a sell rating in a research note on Thursday, July 27th. Piper Jaffray Companies reiterated a buy rating and issued a $246.00 target price on shares of Humana in a research note on Friday, July 14th. Finally, Jefferies Group LLC reiterated a hold rating and issued a $257.00 target price on shares of Humana in a research note on Friday, August 4th. Eleven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $251.60.
Shares of Humana (NYSE:HUM) traded down 1.327% on Tuesday, hitting $238.235. 235,976 shares of the stock traded hands. The stock has a market cap of $34.43 billion, a price-to-earnings ratio of 19.598 and a beta of 0.86. The stock has a 50 day moving average price of $247.97 and a 200-day moving average price of $235.16. Humana has a 52 week low of $165.03 and a 52 week high of $259.76.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The business had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. During the same period in the prior year, the company posted $2.30 EPS. On average, equities research analysts forecast that Humana will post $11.56 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Humana Inc. (HUM) Downgraded by ValuEngine” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2957604/humana-inc-hum-downgraded-by-valuengine.html.
The firm also recently announced a dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 29th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio is currently 13.06%.
In other Humana news, insider Elizabeth D. Bierbower sold 9,786 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $259.00, for a total value of $2,534,574.00. Following the sale, the insider now owns 18,042 shares of the company’s stock, valued at approximately $4,672,878. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the completion of the sale, the chief executive officer now directly owns 80,086 shares in the company, valued at approximately $20,172,061.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,595 shares of company stock worth $14,133,706. 0.80% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in HUM. BlackRock Inc. grew its holdings in Humana by 2,281.7% in the 1st quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after acquiring an additional 11,867,056 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Humana by 7,848.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock worth $377,192,000 after acquiring an additional 1,547,866 shares during the last quarter. FMR LLC grew its holdings in Humana by 29.3% in the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after acquiring an additional 1,479,210 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Humana by 84.3% in the 1st quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after acquiring an additional 1,231,400 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in Humana by 413.8% in the 1st quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock worth $151,723,000 after acquiring an additional 592,772 shares during the last quarter. 95.12% of the stock is currently owned by institutional investors and hedge funds.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.